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DOI: 10.1039/c2an16034jAn electrochemical immuno-biosensor for detecting glycosylated haemoglobin (HbA1c) is reported
based on glassy carbon (GC) electrodes with a mixed layer of an oligo(phenylethynylene) molecular
wire (MW) and an oligo(ethylene glycol) (OEG). The mixed layer is formed from in situ-generated aryl
diazonium cations. To the distal end of the MW, a redox probe 1,10-di(aminomethyl)ferrocene
(FDMA) was attached followed by the covalent attachment of an epitope N-glycosylated pentapeptide
(GPP), an analogon to HbA1c, to which an anti-HbA1c monocolonal antibody IgG can selectively
bind. HbA1c was detected by a competitive inhibition assay based on the competition for binding to
anti-HbA1c IgG antibodies between the analyte in solution, HbA1c, and the surface bound epitope
GPP. Exposure of the GPP modified sensing interface to the mixture of anti-HbA1c IgG antibody and
HbA1c results in the attenuation of ferrocene electrochemistry due to free antibody binding to the
interface. Higher concentrations of analyte led to higher Faradaic currents as less anti-HbA1c IgG is
available to bind to the electrode surface. It was observed that there is a good linear relationship
between the relative Faradaic current of FDMA and the concentration of HbA1c from 4.5% to 15.1%
of total haemoglobin in serum without the need for washing or rinsing steps.Introduction
HbA1c is a stable minor haemoglobin variant formed by a non-
enzymatic reaction of glucose with N-terminal valine of an adult
haemoglobin’s b chain in the human body. Thus, HbA1c is the
main diabetes marker protein for monitoring a person’s average
blood sugar level over the preceding 2 to 3 months.1 Based on
a direct relationship between HbA1c and diabetic complications,
recent guidelines for the management of diabetes now stress the
importance of HbA1c monitoring.2,3 The non-enzymatic origin
makes the direct analysis of glycosylated haemoglobin more
difficult in comparison with the diagnosis of other analytes that
involve enzymatic reactions. Due to the importance of HbA1c
monitoring, numerous analytical methods were developed for its
analysis, such as cation-exchange,4,5 boronate affinity chroma-
tography,6–8 agarose gel electrophoresis,9 colorimetric
methods,10,11 spectroscopic measurements,12–14 and massaSchool of Chemistry and The Australian Centre for NanoMedicine,
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10.1039/c2an16034jspectroscopy.15 For clinical analyses, boronate-affinity chroma-
tography and cation-exchange chromatography in particular are
widely used.16 High performance liquid chromatography
(HPLC), is still considered the standard reference method
however. Nevertheless, the main issue with these methods are
they tend to be time-consuming, expensive, and can give false
results due to the coexistence of genetic variants and other
chemically modified derivatives of haemoglobin.25
Electrochemical affinity sensors have considerable potential
with regards to developing portable analytical devices for
detecting HbA1c. This is because electrochemical methods are
compatible with miniaturization and with measurements in
complex samples such as blood.17 However, the majority of these
sensing interfaces are based on boronate-affinity7,18–23 and
involve enzyme labelling.8,24 To date the more reliable method of
distinguishing the different variants of haemoglobin is using
antibodies that are specific for the glycosylated amino terminus
of the b chain or other adducts.26,27 Hence the development of an
electrochemical immunosensors for detecting HbA1c with high
selectivity and simplicity is required.
In this study, a competitive inhibition assay for detecting
HbA1c was developed using a N-glycosylated pentapeptide
(GPP) as an HbA1c analogon. The proposed immunosensor is
inspired by a recently developed electrochemical immunosensor
based on the modulation of amperometric signals of surface
bound redox species when immersed in a protein environment.28
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and oligo(ethylene glycol) (OEG) was attached onto a glassy
carbon (GC) electrode. 1,10-di(aminomethyl)ferrocene (FDMA)
was then attached to the end of the MW followed by an epitope
(the structural feature an antibody selectively recognises) to
which an antibody binds to give the final fabricated immuno-
sensor interface. In the work presented here, the epitope
employed is a pentapeptide, glycolysated-VHLTP (GPP).
Transduction in this system is based on the amperometric signal
of surface bound ferrocene moiety being attenuated when anti-
bodies bind to the epitope due to the immersion of the ferrocene
into a protein environment. This immunosensing concept is
applicable to either the detection of antibodies28 or the detection
of small molecules28–30 such as drugs and pesticides. Here the
concept is applied to the detection of HbA1c. Unlike small
molecules that the system was designed to detect, HbA1c and
haemoglobin actually represent the detection of large proteins.
Hence, this study represents a broadening of the scope of the thus
far reported immunosensing technology. In this study,
a competitive inhibition assay for the detection of HbA1c has
been investigated as shown in Scheme 1.
The procedure for fabricating the sensing interface (Scheme 1)
is described in the supporting information.‡ Briefly, after the
surface modification of a GC electrode with mixed layer of MW/Scheme 1 Schematic of the design for a competitive inhibition assay for detec
the red triangle represents HbA1c and the pink surface bound triangle is the g
is inserted.
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a molar ratio of 1 : 50, FDMA was attached to the free
carboxylic acid moiety at the end of theMW. Characterization of
this interface, including the amount of FDMA and other species
attached, was performed previously.30 To the distal free amine of
FDMA, the GPP was attached using the classical carbodiimide
coupling. Note that the GPP (Scheme 1) contains no free amine
and only a single carboxyl group. Therefore only one coupling
reaction can occur and a well-defined sensing interface is ach-
ieved. After the attachment of GPP, the electrochemistry of
FDMA modified GC electrode surfaces showed only a minor
attenuation in current intensity. This result is encouraging as it
indicates the peptide does not block the surface electrochemistry,
a necessary condition for the sensor to be able to operate.
Complexation of the human anti-HbA1c monoclonal IgG anti-
body with the GPP attached to the distal end of the MW results
in an obvious attenuation of the ferrocene electrochemistry
(Fig. 1), as observed previously for other antibody-epitope
combinations.28,29 In this study, the anti-HbA1c IgG antibody
binding to the sensing interface results in the FDMA electro-
chemistry being suppressed by 67% 4% (95% confidence, n¼ 6)
of the original value prior to exposure to the anti-HbA1c
IgG antibody.ting HbA1c. The anti-HbA1c IgG antibody is represented by the blue Y,
lycolylated pentapeptide. The structure of GPP (N-glycosylated-VHLTP)
Fig. 1 Representative square wave voltammograms (SWV) for FDMA
modified GC electrodes after the stepwise attachment of (a) GPP, and (b)
anti-HbA1c IgG antibody.Three controls were performed to verify that the change in
current was due to a specific interaction between the anti-HbA1c
antibody IgG and the surface bound GPP epitope. These were 1)
the carboxyl on the GPP was not activated with EDC/NHS and
hence did not couple to the MW. 2) the anti-HbA1c antibody
IgGwas pre-complexed with 2 mMGPP for 3 h at 4 C, such that
the antibody had no available binding sites to complex with the
surface and 3) the biosensing interface was incubated in either the
wrong IgG, in this case 10 mg mL1 anti-biotin IgG antibody, or
different type of proteins, such as 10 mg mL1 of bovine serum
albumin. In all three controls only a minor decrease in current
(5% of current intensity determined by SWV) was observed.
As a consequence of the anti-HbA1c IgG antibody selectively
binding to the sensing interface, a competitive inhibition assay
(Scheme 1) was developed for detecting the amount of HbA1c in
human serum. In a competitive inhibition assay, the final bio-
sensing interface is the FDMA and GPP attached to the MW in
the absence of anti-HbA1c IgG antibody. The anti-HbA1c IgG
antibody is then introduced into a sample solution where it can
complex with the analyte present. Any remaining uncomplexed
anti-HbA1c IgG is then free to bind with the epitope and
the FDMA electrochemistry was attenuated. Hence the greater
the amount of analyte, the more anti-HbA1c IgG complexes with
the analyte, the lower the amount of free anti-HbA1c IgG
available to bind with the epitope and thus the higher the elec-
trochemical signal. In order to verify that the competitive inhi-
bition assay system is viable to use in a complex matrix such as
human serum, the sensing interface was incubated in the serum
containing 2 mg mL1 of anti-HbA1c IgG antibody and 13.5% ofFig. 2 A representative SWV for FDMA modified GC electrodes after
(a) the attachment of GPP, and (b) the subsequent incubation in
a mixture containing 2 mg mL1 of anti-HbA1c IgG antibody and 13.5%
HbA1c.HbA1c (Fig. 2). As can be seen from Fig. 2 there is some current
attenuation, suggesting there is free antibody in solution that has
not complexed with the HbA1c, and hence can bind to the
sensing interface. The current decreased by 29%  2% (95%
confidence, n ¼ 6). This is a significantly lower current attenu-
ation (29%, Fig. 2) compared with that observed when the GPP
modified interface was exposed to anti-HbA1c IgG (67%, Fig. 1)
in the absence of the analyte (HbA1c). The lower current
attenuation in the presence of the HbA1c indicates that some of
the anti-HbA1c IgG antibody is complexed with the HbA1c and
hence cannot bind to the sensing interface.
HbA1c standards, with percentages of HbA1c of 4.5%, 8%,
12.1% and 15.1%, but with the same total amount of haemo-
globin (glycosylated and non-glycosylated) were used to
construct a calibration curve. Note that these HbA1c standards
were prepared in human serum. HbA1c samples with other
concentrations were also prepared by mixing the stock solution
of HbA1c standard R1 (4.5%) and another stock solution of
HbA1c standard, R4 (15.1%) in different molar ratios. The
calibration curve was plotted as shown in Fig. 3 and the studied
HbA1c concentration range has covered the expected clinical
range of haemoglobin. Fig. 3 shows that the relative current
obtained is linear within the range of 4.5% to 15.1% (the
percentage of HbA1c to the total amount of haemoglobin).
In control experiments, where the sensing interface was
exposed to a mixture of anti-HbA1c antibody IgG and 2 mM of
pentapeptide VHLTP (peptide that was not glycosylated), or was
exposed to haemoglobin, the current attenuation was compa-
rable to when the sensor was incubated in a serum only con-
taining the anti-HbA1c IgG and no HbA1c (See Fig. S4 for
example).
In summary, an electrochemical immunosensor has been
developed for detecting HbA1c. Firstly, GC electrodes were
modified with mixed layer of MW and OEG. Then the redox
species FDMA was covalently attached to the interface followed
by the attachment of an epitope, a glycosylated pentapeptide.
The binding of anti-HbA1c IgG to this sensing interface causes
the attenuation of the FDMA electrochemistry. A competitive
inhibition assay was employed for detecting HbA1c within the
clinical range (5%–20%) in undiluted human serum. A linear
relationship was obtained between the relative current and theFig. 3 Calibration curve for HbA1c measured with the competitive
inhibition assay. The total concentration of haemoglobin was about 15 g
dL1. Four calibrators were pre-mixed with 2 mg mL1 of anti-HbA1c
monoclonal antibody IgG for 30 min at 4 C, respectively. The mixture
was then drop-coated onto the GPP modified sensing interface. Each
data point represents the average value of six GC electrodes.
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concentration of HbA1c. The sensing system provides a sensitive
and applicable approach for detecting HbA1c.
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